Report Description
Dengue Treatment Market Outlook
The global dengue treatment market size was valued at USD 296 Mn in 2019 and is projected to reach USD 727 Mn by 2027 expanding at a CAGR of 13.3 % during the forecast period, 2020-2027. Dengue is the most rapidly spreading mosquito-borne viral disease in the world. Dengue fever, also known as break-bone fever, leads to severe flu.
Dengue is caused by an RNA virus of mosquitos that belong to the Flaviviridae family and several other species of mosquitos such as Aedes. Symptoms of dengue include fever, headache vomiting, muscle, joint pain, and characteristic skin rash. The patient recovers from dengue within seven days; however, in some cases, it can develop into life-threatening dengue hemorrhagic fever.
The global dengue treatment market is anticipated grow due to the rise in the burden of dengue in tropical and subtropical regions. Increase in government funding to fight against dengue and unmet market needs of managing this burden globally boosts the dengue treatment market.
Dengue Treatment Market Dynamics
The market is driven by factors such as growing awareness about prevention and control of dengue, robust promising pipeline of manufacturers for dengue treatment, increasing prevalence of dengue.
However, stringent government regulations regarding drug approval, and lack of government facilities and skilled medical professionals in under developed countries are the factors expected to hamper the market growth. Whereas, rising R&D investment and activities is expected to create lucrative opportunities in the market.
Dengue Treatment Market Segment Insights
Type Segment Analysis
On the basis of type, the global dengue treatment market is bifurcated into drug and vaccine. The drug segment is expected to holds a major share of the market, in terms of volume, due to easy availability and low cost prices. The vaccine segment is estimated to at a significant CAGR of around 35.3% during the forecast period.
Route of Administration Segment Analysis
Based on route of administration the global dengue treatment market is classified into oral, and parenteral. The parenteral segment is projected to hold a major share of the market due to their high cost and wide adoption, as patients need instant recovery from the dengue virus. This, in turn, increases the demand for the vaccine using parenteral route of the administration during the forecast period.
Regional Analysis
In terms of region the market has been fragmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Asia Pacific is a promising region for the market. It constituted around half of the market in terms of share in 2019.
The market in the region is projected to expand at a CAGR of 14.0% during the forecast period. The demand for dengue treatment is expected to rise due to the rapid increase in prevalence of dengue in the region during the forecast period.
Key Benefits for Industry Participants & Stakeholders
- In-depth Analysis of the Global Dengue Treatment Market
- Historical, Current and Projected Market Size in terms of Value and Volume
- Potential & Niche Segments and Regions Exhibiting Promising Growth Covered
- Industry Drivers, Restraints and Opportunities Covered in the Study
- Recent Industry Trends and Developments
- Competitive Landscape & Strategies of Key Players
- Neutral Perspective on Global Dengue Treatment Market Performance
Segments
Type
Route of Administration
End-user
- Hospitals
- Homecare
- Specialty Clinics
- Others
Region
- North America
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Europe
- Germany
- France
- Italy
- UK
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of Asia Pacific
- Middle East & Africa (MEA)
- Saudi Arabia
- South Africa
- UAE
- Rest of MEA
Key Market Players Profiled in the Report
Competitive Landscape
Key players in the market include Sanofi, and Johnson & Johnson Services, Inc. These companies are considered as key manufacturers of dengue treatment based on their revenue, research development (R&D) activities, product offerings, regional presence, and supply chain management system.
The players are adopting key strategies such as acquisition, collaborations, and geographical expansion where potential opportunity for the dengue treatment extraction is added in the company’s capacity. For instance,
- In February 2020, Johnson & Johnson Services, Inc. announced that its subsidary Janssen Pharmaceutical Companies is further accelerating its investigational coronavirus vaccine program by collaborating with the Biomedical Advanced Research & Development Authority (BARDA), a part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the US Department of Health & Human Services.
- In December 2018, Merck & Co., Inc., and Instituto Butantan, a non-profit producer of immunobiologic products for Brazil entered into a collaborative agreement to develop vaccines to protect against dengue virus disease, the mosquito-borne infection. Instituto Butantan and Merck & Co., Inc. have licensed certain rights from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S National Institutes of Health (NIH), for the development of live attenuated tetravalent vaccines (LATVs).
Frequently Asked Questions
Major manufactures include, Sanofi, and Johnson & Johnson Services, Inc.
Hospitals and Homecare are the key end-users driving the dengue treatment market.
The base year considered for the global dengue treatment market report is 2019. The complete analysis period is 2017 to 2027, wherein, 2017 & 2018 are the historic years and the forecast is provided from 2020 to 2027
The market is expected to witness decline of over 0.6% between 2019 and 2020 owing to the negative impact of COVID 19 pandemic on the dengue treatments market. The shutdown of production activities, restrictions on transportation activities, and temporary decline in demand for dengue treatments are some of the prime reasons responsible for this market trend.
Factors such as competitive strength and market positioning are key areas considered while selecting top companies to be profiled.
The increasing government initiatives to fight against dengue, promising dengue pipeline, growing prevalence of dengue, and rising awareness of dengue are the factors expected to drive the market growth during forecast period.
In addition to market size (in US$ Million), Market Volume (in Million unit), and Company Market Share (in % for base year 2019), other data such as Pricing analysis for year 2017 to 2027 (estimated pricing analysis) is provided, Pipeline Analysis for dengue treatment is also available in final report.
According to this Growth Market Reports report, the market from dengue treatment is likely to register a CAGR of 13.3% during forecast period 2020-2027, with an anticipated valuation of US$ 727 million by the end of the 2027.
Yes, the report includes the traveler’s data in the final report. The data is provided as per the data availability and dengue cases reported in particular countries.
Additional company profiles can be provided on request.
Table Of Content
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Dengue Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Dengue Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Dengue Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Pipeline Analysis
4.5 Global Dengue Treatment Market Size & Forecast, 2017-2027
4.5.1 Dengue Treatment Market Size and Y-o-Y Growth
4.5.2 Dengue Treatment Market Absolute $ Opportunity
4.6 Pricing Analysis & Forecast, 2017-2027
4.7 Travellers Data
Chapter 5 Global Dengue Treatment Market Analysis and Forecast By Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Type
5.1.2 Basis Point Share (BPS) Analysis By Type
5.1.3 Absolute $ Opportunity Assessment By Type
5.2 Dengue Treatment Market Size & Volume Forecast By Type
5.2.1 Drug
5.2.2 Vaccines
5.3 Market Attractiveness Analysis By Type
Chapter 6 Global Dengue Treatment Market Analysis and Forecast By Route of Administration
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Route of Administration
6.1.2 Basis Point Share (BPS) Analysis By Route of Administration
6.1.3 Absolute $ Opportunity Assessment By Route of Administration
6.2 Dengue Treatment Market Size & Volume Forecast By Route of Administration
6.2.1 Oral
6.2.2 Parenteral
6.3 Market Attractiveness Analysis By Route of Administration
Chapter 7 Global Dengue Treatment Market Analysis and Forecast By End-user
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By End-user
7.1.2 Basis Point Share (BPS) Analysis By End-user
7.1.3 Absolute $ Opportunity Assessment By End-user
7.2 Dengue Treatment Market Size & Volume Forecast By End-user
7.2.1 Hospitals
7.2.2 Homecare
7.2.3 Specialty Clinics
7.2.4 Others
7.3 Market Attractiveness Analysis By End-user
Chapter 8 Global Dengue Treatment Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Dengue Treatment Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Dengue Treatment Analysis and Forecast
10.1 Introduction
10.2 North America Dengue Treatment Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Dengue Treatment Market Size & Volume Forecast By Type
10.6.1 Drug
10.6.2 Vaccines
10.7 Basis Point Share (BPS) Analysis By Type
10.8 Absolute $ Opportunity Assessment By Type
10.9 Market Attractiveness Analysis By Type
10.10 North America Dengue Treatment Market Size & Volume Forecast By Route of Administration
10.10.1 Oral
10.10.2 Parenteral
10.11 Basis Point Share (BPS) Analysis By Route of Administration
10.12 Absolute $ Opportunity Assessment By Route of Administration
10.13 Market Attractiveness Analysis By Route of Administration
10.14 North America Dengue Treatment Market Size & Volume Forecast By End-user
10.14.1 Hospitals
10.14.2 Homecare
10.14.3 Specialty Clinics
10.14.4 Others
10.15 Basis Point Share (BPS) Analysis By End-user
10.16 Absolute $ Opportunity Assessment By End-user
10.17 Market Attractiveness Analysis By End-user
Chapter 11 Europe Dengue Treatment Analysis and Forecast
11.1 Introduction
11.2 Europe Dengue Treatment Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Dengue Treatment Market Size & Volume Forecast By Type
11.6.1 Drug
11.6.2 Vaccines
11.7 Basis Point Share (BPS) Analysis By Type
11.8 Absolute $ Opportunity Assessment By Type
11.9 Market Attractiveness Analysis By Type
11.10 Europe Dengue Treatment Market Size & Volume Forecast By Route of Administration
11.10.1 Oral
11.10.2 Parenteral
11.11 Basis Point Share (BPS) Analysis By Route of Administration
11.12 Absolute $ Opportunity Assessment By Route of Administration
11.13 Market Attractiveness Analysis By Route of Administration
11.14 Europe Dengue Treatment Market Size & Volume Forecast By End-user
11.14.1 Hospitals
11.14.2 Homecare
11.14.3 Specialty Clinics
11.14.4 Others
11.15 Basis Point Share (BPS) Analysis By End-user
11.16 Absolute $ Opportunity Assessment By End-user
11.17 Market Attractiveness Analysis By End-user
Chapter 12 Asia Pacific Dengue Treatment Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Dengue Treatment Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Dengue Treatment Market Size & Volume Forecast By Type
12.6.1 Drug
12.6.2 Vaccines
12.7 Basis Point Share (BPS) Analysis By Type
12.8 Absolute $ Opportunity Assessment By Type
12.9 Market Attractiveness Analysis By Type
12.10 Asia Pacific Dengue Treatment Market Size & Volume Forecast By Route of Administration
12.10.1 Oral
12.10.2 Parenteral
12.11 Basis Point Share (BPS) Analysis By Route of Administration
12.12 Absolute $ Opportunity Assessment By Route of Administration
12.13 Market Attractiveness Analysis By Route of Administration
12.14 Asia Pacific Dengue Treatment Market Size & Volume Forecast By End-user
12.14.1 Hospitals
12.14.2 Homecare
12.14.3 Specialty Clinics
12.14.4 Others
12.15 Basis Point Share (BPS) Analysis By End-user
12.16 Absolute $ Opportunity Assessment By End-user
12.17 Market Attractiveness Analysis By End-user
Chapter 13 Latin America Dengue Treatment Analysis and Forecast
13.1 Introduction
13.2 Latin America Dengue Treatment Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Dengue Treatment Market Size & Volume Forecast By Type
13.6.1 Drug
13.6.2 Vaccines
13.7 Basis Point Share (BPS) Analysis By Type
13.8 Absolute $ Opportunity Assessment By Type
13.9 Market Attractiveness Analysis By Type
13.10 Latin America Dengue Treatment Market Size & Volume Forecast By Route of Administration
13.10.1 Oral
13.10.2 Parenteral
13.11 Basis Point Share (BPS) Analysis By Route of Administration
13.12 Absolute $ Opportunity Assessment By Route of Administration
13.13 Market Attractiveness Analysis By Route of Administration
13.14 Latin America Dengue Treatment Market Size & Volume Forecast By End-user
13.14.1 Hospitals
13.14.2 Homecare
13.14.3 Specialty Clinics
13.14.4 Others
13.15 Basis Point Share (BPS) Analysis By End-user
13.16 Absolute $ Opportunity Assessment By End-user
13.17 Market Attractiveness Analysis By End-user
Chapter 14 Middle East & Africa (MEA) Dengue Treatment Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Dengue Treatment Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By Type
14.6.1 Drug
14.6.2 Vaccines
14.7 Basis Point Share (BPS) Analysis By Type
14.8 Absolute $ Opportunity Assessment By Type
14.9 Market Attractiveness Analysis By Type
14.10 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By Route of Administration
14.10.1 Oral
14.10.2 Parenteral
14.11 Basis Point Share (BPS) Analysis By Route of Administration
14.12 Absolute $ Opportunity Assessment By Route of Administration
14.13 Market Attractiveness Analysis By Route of Administration
14.14 Middle East & Africa (MEA) Dengue Treatment Market Size & Volume Forecast By End-user
14.14.1 Hospitals
14.14.2 Homecare
14.14.3 Specialty Clinics
14.14.4 Others
14.15 Basis Point Share (BPS) Analysis By End-user
14.16 Absolute $ Opportunity Assessment By End-user
14.17 Market Attractiveness Analysis By End-user
Chapter 15 Competition Landscape
15.1 Dengue Treatment Market: Competitive Dashboard
15.2 Global Dengue Treatment Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 GeneOne Life Science, Inc
15.3.2 Johnson & Johnson
15.3.3 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
15.3.4 Novartis AG
15.3.5 Sanofi
15.3.6 Serum Institute of India Pvt. Ltd
15.3.7 Sun Pharmaceutical Industries Ltd.
15.3.8 Takeda Pharmaceutical Company Limited